Related references
Note: Only part of the references are listed.Dose escalation in radiotherapy for incomplete transarterial chemoembolization of hepatocellular carcinoma
Hwa Kyung Byun et al.
STRAHLENTHERAPIE UND ONKOLOGIE (2020)
Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors
Matthew H. Taylor et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial
Vicky Makker et al.
LANCET ONCOLOGY (2019)
Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC).
Richard S. Finn et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Cabozantinib for advanced hepatocellular carcinoma
Masatoshi Kudo
HEPATOBILIARY SURGERY AND NUTRITION (2019)
Treatment Lines in Hepatocellular Carcinoma
Henning Wege et al.
VISCERAL MEDICINE (2019)
747PA phase Ib trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): Updated results
J Llovet et al.
ANNALS OF ONCOLOGY (2019)
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2019)
Radiation Therapy in HCC: What Data Exist and What Data Do We Need to Incorporate into Guidelines?
Melody J. Xu et al.
SEMINARS IN LIVER DISEASE (2019)
Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics
Priti S. Hegde et al.
SEMINARS IN CANCER BIOLOGY (2018)
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
Peter R. Galle et al.
JOURNAL OF HEPATOLOGY (2018)
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Masatoshi Kudo et al.
LANCET (2018)
Using immunotherapy to boost the abscopal effect
Wilfred Ngwa et al.
NATURE REVIEWS CANCER (2018)
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Jordi Bruix et al.
LANCET (2017)
Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade
Martina Schmittnaegel et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy
Etienne Becht et al.
CLINICAL CANCER RESEARCH (2016)
Dual inhibition of Ang-2 and VEGF receptors normalizes tumor vasculature and prolongs survival in glioblastoma by altering macrophages
Teresa E. Peterson et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival
Jonas Kloepper et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Therapeutic Strategies in HCC: Radiation Modalities
R. Gallicchio et al.
BIOMED RESEARCH INTERNATIONAL (2016)
Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp
Khalid O. Alfarouk et al.
CANCER CELL INTERNATIONAL (2015)
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
Giulia Siravegna et al.
NATURE MEDICINE (2015)
Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models
Kiyoshi Okamoto et al.
CANCER LETTERS (2013)
Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy
Yuhui Huang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Myeloid-derived suppressor cells as regulators of the immune system
Dmitry I. Gabrilovich et al.
NATURE REVIEWS IMMUNOLOGY (2009)
E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition
Junji Matsui et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Share Paper
